Role of interferon in melanoma: old hopes and new perspectives

References

• Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 1957;147:258–267.
   PubMed Web of Science ®Google Scholar
• Lindenmann J. Induction of chick interferon: procedures of the original experiments. Methods Enzymol. 1981;78:181–188.
   PubMedGoogle Scholar
• Pestka S, Langer JA, Zoon KC, et al. Interferons and their actions. Annu Rev Biochem. 1987;56:727–777.
   PubMed Web of Science ®Google Scholar
• Pestka S. Interferon standards and general abbreviations. Methods Enzymol. 1986;119:14–23.
   PubMed Web of Science ®Google Scholar
• Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol. 2003;4:69–77.
   PubMed Web of Science ®Google Scholar
• Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994;264:1415–1421.
   PubMed Web of Science ®Google Scholar
• Ihle JN. The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv Immunol. 1995;60:1–35.
   PubMed Web of Science ®Google Scholar
• Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol. 1997;15:563–591.
   PubMed Web of Science ®Google Scholar
• Chen J, Baig E, Fish EN. Diversity and relatedness among the type I interferons. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res. 2004;24:687–698.
   PubMed Web of Science ®Google Scholar
• Platanias LC. The p38 mitogen-activated protein kinase pathway and its role in interferon signaling. Pharmacol Ther. 2003;98:129–142.
   PubMed Web of Science ®Google Scholar
• Rafique I, Kirkwood JM, Tarhini AA. Immune checkpoint blockade and interferon-α in melanoma. Semin Oncol. 2015;42:436–447.
   PubMed Web of Science ®Google Scholar
• Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol. 2006;6:836–848.
   PubMed Web of Science ®Google Scholar
• Zhou Z, Hamming OJ, Ank N, et al. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol. 2007;81:7749–7758.
   PubMed Web of Science ®Google Scholar
• Vilcek J. Novel interferons. Nat Immunol. 2003;4:8–9.
   PubMed Web of Science ®Google Scholar
• Miller CHT, Maher SG, Young HA. Clinical use of interferon-gamma. Ann N Y Acad Sci. 2009;1182:69–79.
   PubMed Web of Science ®Google Scholar
• Platanias LC. Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol. 2005;5:375–386.
   PubMed Web of Science ®Google Scholar
• Krasagakis K, Garbe C, Krüger S, et al. Effects of interferons on cultured human melanocytes in vitro: interferon-beta but not-alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype. J Invest Dermatol. 1991;97:364–372.
   PubMed Web of Science ®Google Scholar
• Roh MR, Zheng Z, Kim HS, et al. Difference of interferon-α and interferon-β on melanoma growth and lymph node metastasis in mice. Melanoma Res. 2013;23:114–124.
   PubMed Web of Science ®Google Scholar
• Kubo H, Ashida A, Matsumoto K, et al. Interferon-beta therapy for malignant melanoma: the dose is crucial for inhibition of proliferation and induction of apoptosis of melanoma cells. Arch Dermatol Res. 2008;300:297–301.
   PubMed Web of Science ®Google Scholar
• Horikoshi T, Fukuzawa K, Hanada N, et al. In vitro comparative study of the antitumor effects of human interferon-alpha, beta and gamma on the growth and invasive potential of human melanoma cells. J Dermatol. 1995;22:631–636.
   PubMedGoogle Scholar
• Raig ET, Jones NB, Varker KA, et al. VEGF secretion is inhibited by interferon-alpha in several melanoma cell lines. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res. 2008;28:553–561.
   PubMed Web of Science ®Google Scholar
• Bölling B, Fandrey J, Frosch PJ, et al. VEGF production, cell proliferation and apoptosis of human IGR 1 melanoma cells under nIFN-alpha/beta and rIFN-gamma treatment. Exp Dermatol. 2000;9:327–335.
   PubMed Web of Science ®Google Scholar
• McMillan TJ, Rao J, Everett CA, et al. Interferon-induced alterations in metastatic capacity, class-1 antigen expression and natural killer cell sensitivity of melanoma cells. Int J Cancer J Int Cancer. 1987;40:659–663.
   PubMed Web of Science ®Google Scholar
• Basham TY, Bourgeade MF, Creasey AA, et al. Interferon increases HLA synthesis in melanoma cells: interferon-resistant and -sensitive cell lines. Proc Natl Acad Sci U S A. 1982;79:3265–3269.
   PubMed Web of Science ®Google Scholar
• Giacomini P, Fraioli R, Calabrò AM, et al. Class I major histocompatibility complex enhancement by recombinant leukocyte interferon in the peripheral blood mononuclear cells and plasma of melanoma patients. Cancer Res. 1991;51:652–656.
   PubMed Web of Science ®Google Scholar
• Heise R, Amann PM, Ensslen S, et al. Interferon alpha signalling and its relevance for the upregulatory effect of transporter proteins associated with antigen processing (TAP) in patients with malignant melanoma. slominski AT editor. Plos One. 2016;11:e0146325.
   PubMedGoogle Scholar
• Losinno C, Wines BD, Johns TG, et al. Natural killer cell activity against cultured melanoma cells: a dye-reduction technique with studies on augmented activity by interferon subtypes. Nat Immun. 1992;11:215–224.
   PubMedGoogle Scholar
• Palmer KJ, Harries M, Gore ME, et al. Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC). Clin Exp Immunol. 2000;119:412–418.
   PubMed Web of Science ®Google Scholar
• Lesinski GB, Anghelina M, Zimmerer J, et al. The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse. J Clin Invest. 2003;112:170–180.
   PubMed Web of Science ®Google Scholar
• Kolumam GA, Thomas S, Thompson LJ, et al. Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med. 2005;202:637–650.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Richards T, Zarour HM, et al. Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer. 2002;95:1101–1112.
   PubMed Web of Science ®Google Scholar
• Paquette RL, Hsu NC, Kiertscher SM, et al. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol. 1998;64:358–367.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Geiger T, Alkan S, et al. Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells. J Exp Med. 1993;178:1655–1663.
   PubMed Web of Science ®Google Scholar
• Wenner CA, Güler ML, Macatonia SE, et al. Roles of IFN-gamma and IFN-alpha in IL-12-induced T helper cell-1 development. J Immunol Baltim Md. 1950/1996;156:1442–1447.
   Google Scholar
• Håkansson A, Gustafsson B, Krysander L, et al. Effect of IFN-alpha on tumor-infiltrating mononuclear cells and regressive changes in metastatic malignant melanoma. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res. 1998;18:33–39.
   PubMed Web of Science ®Google Scholar
• Håkansson A, Gustafsson B, Krysander L, et al. Effect of interferon-alpha on the expression of tumour necrosis factor-alpha by metastatic malignant melanoma in vivo. Melanoma Res. 1997;7:139–145.
   PubMed Web of Science ®Google Scholar
• Ismail A, Yusuf N. Type I interferons: key players in normal skin and select cutaneous malignancies. Dermatol Res Pract. 2014;2014:847545.
   PubMedGoogle Scholar
• Moschos SJ, Edington HD, Land SR, et al. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24:3164–3171.
   PubMed Web of Science ®Google Scholar
• Di Pucchio T, Pilla L, Capone I, et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res. 2006;66:4943–4951.
   PubMed Web of Science ®Google Scholar
• Tsavaris N, Baxevanis C, Kosmidis P, et al. The prognostic significance of immune changes in patients with renal cancer, melanoma and colorectal cancer, treated with interferon alpha 2b. Cancer Immunol Immunother CII. 1996;43:94–102.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Kirkwood JM. Clinical and immunologic basis of interferon therapy in melanoma. Ann N Y Acad Sci. 2009;1182:47–57.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol Off J Am Soc Clin Oncol. 1996;14:7–17.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sondak VK, et al. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol Off J Am Soc Clin Oncol. 2000;18:2444–2458.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim J, Lawson DH, et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the multicenter eastern cooperative oncology group phase II trial E2696. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19:1430–1436.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Ibrahim JG, Sosman JA, et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol Off J Am Soc Clin Oncol. 2001;19:2370–2380.
   PubMed Web of Science ®Google Scholar
• Garbe C, Radny P, Linse R, et al. Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2008;19:1195–1201.
   PubMed Web of Science ®Google Scholar
• Payne MJ, Argyropoulou K, Lorigan P, et al. Phase II pilot study of intravenous high-dose Interferon with or without maintenance treatment in melanoma at high risk of recurrence. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:185–190.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Suciu S, Rutkowski P, et al. Long term follow up of the EORTC 18952 trial of adjuvant therapy in resected stage IIB–III cutaneous melanoma patients comparing intermediate doses of interferon-alpha-2b (IFN) with observation: ulceration of primary is key determinant for IFN-sensitivity. Eur J Cancer. 2016;55:111–121.
   PubMed Web of Science ®Google Scholar
• Mocellin S, Pasquali S, Rossi CR, et al. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst. 2010;102:493–501.
   PubMed Web of Science ®Google Scholar
• Wheatley K, Ives N, Hancock B, et al. Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rev. 2003;29:241–252.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Suciu S, Testori A, et al. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer Oxf Engl. 1990/2012;48:218–225.
   Web of Science ®Google Scholar
• Eggermont AMM, Suciu S, Testori A, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:3810–3818.
   PubMed Web of Science ®Google Scholar
• Grob JJ, Jouary T, Dréno B, et al. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European association for dermato-oncology (EADO) study. Eur J Cancer Oxf Engl. 1990/2013;49:166–174.
   Web of Science ®Google Scholar
• Wang W, Edington HD, Rao UNM, et al. Modulation of signal transducers and activators of transcription 1 and 3 signaling in melanoma by high-dose IFNalpha2b. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13:1523–1531.
   PubMed Web of Science ®Google Scholar
• Hofmann MA, Kiecker F, Küchler I, et al. Serum TNF-α, B2M and sIL-2R levels are biological correlates of outcome in adjuvant IFN-α2b treatment of patients with melanoma. J Cancer Res Clin Oncol. 2011;137:455–462.
   PubMed Web of Science ®Google Scholar
• Simons DL, Lee G, Kirkwood JM, et al. Interferon signaling patterns in peripheral blood lymphocytes may predict clinical outcome after high-dose interferon therapy in melanoma patients. J Transl Med. 2011;9:52.
   PubMed Web of Science ®Google Scholar
• Håkansson A, Gustafsson B, Krysander L, et al. Tumour-infiltrating lymphocytes in metastatic malignant melanoma and response to interferon alpha treatment. Br J Cancer. 1996;74:670–676.
   PubMed Web of Science ®Google Scholar
• Sasse AD, Sasse EC, Clark LGO, et al. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev. 2007;(1):CD005413.
   PubMedGoogle Scholar
• Ives NJ, Stowe RL, Lorigan P, et al. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patients. J Clin Oncol Off J Am Soc Clin Oncol. 2007;25:5426–5434.
   PubMed Web of Science ®Google Scholar
• Xin Y, Huang Q, Zhang P, et al. Meta-analysis of the safety and efficacy of interferon combined with dacarbazine versus dacarbazine alone in cutaneous malignant melanoma. Medicine (Baltimore). 2016;95:e3406.
   PubMed Web of Science ®Google Scholar
• Brunet JF, Denizot F, Luciani MF, et al. A new member of the immunoglobulin superfamily–CTLA-4. Nature. 1987;328:267–270.
   PubMed Web of Science ®Google Scholar
• Waterhouse P, Penninger JM, Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science. 1995;270:985–988.
   PubMed Web of Science ®Google Scholar
• Hanson DC, Canniff PC, Primiano MJ, et al. Preclinical in vitro characterization of anti-CTLA4 therapeutic antibody CP-675,206. Cancer Res. 2004;64:877–877.
   Google Scholar
• Ribas A, Comin-Anduix B, Economou JS, et al. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res Off J Am Assoc Cancer Res. 2009;15:390–399.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Cherian J, Moschos SJ, et al. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:322–328.
   PubMed Web of Science ®Google Scholar
• Home - ClinicalTrials.gov [Internet]. [cited 2013 Sep 18]. Available from: http://clinicaltrials.gov/.
   Google Scholar
• Zou W, Wolchok JD, Chen L. PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med. 2016;8:328rv4.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Taube JM, Anders RA, et al. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275–287.
   PubMed Web of Science ®Google Scholar
• Gerner MY, Heltemes-Harris LM, Fife BT, et al. Cutting edge: IL-12 and type I IFN differentially program CD8 T cells for programmed death 1 re-expression levels and tumor control. J Immunol Baltim Md. 1950/2013;191:1011–1015.
   Google Scholar
• Mühlbauer M, Fleck M, Schütz C, et al. PD-L1 is induced in hepatocytes by viral infection and by interferon-alpha and -gamma and mediates T cell apoptosis. J Hepatol. 2006;45:520–528.
   PubMed Web of Science ®Google Scholar
• Gowrishankar K, Gunatilake D, Gallagher SJ, et al. Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB. Plos ONE [Internet]. 2015; 10: cited 2016 May 8]. Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386825/
   PubMed Web of Science ®Google Scholar
• Zarour HM, Tawbi H, Tarhini AA, et al. Study of anti-PD-1 antibody pembrolizumab and pegylated-interferon alfa-2b (Peg-IFN) for advanced melanoma. J Clin Oncol [Internet]. 2015;33(suppl; abstr e20018):cited 2016 May 9. Available from http://meetinglibrary.asco.org/content/152481-156
   Google Scholar
• Kumar KGS, Liu J, Li Y, et al. Raf inhibitor stabilizes receptor for the type I interferon but inhibits its anti-proliferative effects in human malignant melanoma cells. Cancer Biol Ther. 2007;6:1437–1441.
   PubMed Web of Science ®Google Scholar
• Frederick DT, Piris A, Cogdill AP, et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2013;19:1225–1231.
   PubMed Web of Science ®Google Scholar
• Sapkota B, Hill CE, Pollack BP. Vemurafenib enhances MHC induction in BRAF(V600E) homozygous melanoma cells. Oncoimmunology. 2013;2:e22890.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Grimaldi AM, Acquavella N, et al. Future perspectives in melanoma research. meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012. J Transl Med. 2013;11:137.
   PubMed Web of Science ®Google Scholar
• Ferrari De AL, Ngiow SF, Stannard K, et al. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res. 2014;74:7298–7308.
   PubMed Web of Science ®Google Scholar
• Sanlorenzo M, Vujic I, Moy A, et al. Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives. Expert Opin Biol Ther. 2015;15:1491–1500.
   PubMed Web of Science ®Google Scholar
• Parker BS, Rautela J, Hertzog PJ. Antitumour actions of interferons: implications for cancer therapy. Nat Rev Cancer. 2016;16:131–144.
   PubMed Web of Science ®Google Scholar
• Fuchs SY. Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy. J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res. 2013;33:211–225.
   PubMed Web of Science ®Google Scholar
• Zheng H, Qian J, Varghese B, et al. Ligand-stimulated downregulation of the alpha interferon receptor: role of protein kinase D2. Mol Cell Biol. 2011;31:710–720.
   PubMed Web of Science ®Google Scholar
• Zheng H, Qian J, Carbone CJ, et al. Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis. Blood. 2011;118:4003–4006.
   PubMed Web of Science ®Google Scholar
• Huangfu W-C, Qian J, Liu C, et al. Inflammatory signaling compromises cell responses to interferon alpha. Oncogene. 2012;31:161–172.
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, HuangFu W-C, Dong G, et al. Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses. Oncogene. 2013;32:4214–4221.
   PubMed Web of Science ®Google Scholar
• Song MM, Shuai K. The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem. 1998;273:35056–35062.
   PubMed Web of Science ®Google Scholar
• Porritt RA, Hertzog PJ. Dynamic control of type I IFN signalling by an integrated network of negative regulators. Trends Immunol. 2015;36:150–160.
   PubMed Web of Science ®Google Scholar
• Pan M, Kalie E, Scaglione BJ, et al. Mutation of the IFNAR-1 receptor binding site of human IFN-alpha2 generates type I IFN competitive antagonists. Biochemistry (Mosc.). 2008;47:12018–12027.
   Web of Science ®Google Scholar
• Eggermont AMM, Suciu S, Santinami M, et al. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet Lond Engl. 2008;372:117–126.
   PubMed Web of Science ®Google Scholar
• Aranda F, Vacchelli E, Obrist F, et al. Trial Watch: toll-like receptor agonists in oncological indications. Oncoimmunology. 2014;3:e29179.
   PubMedGoogle Scholar
• Qin M, Li Y, Yang X, et al. Safety of Toll-like receptor 9 agonists: a systematic review and meta-analysis. Immunopharmacol Immunotoxicol. 2014;36:251–260.
   PubMed Web of Science ®Google Scholar
• Hartman LLR, Crawford JR, Makale MT, et al. Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol. 2014;36:451–457.
   PubMed Web of Science ®Google Scholar
• Jeung H-C, Moon YW, Rha SY, et al. Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2008;19:520–526.
   PubMed Web of Science ®Google Scholar
• Kemeny N, Yagoda A, Wang Y, et al. Randomized trial of standard therapy with or without poly I:C in patients with superficial bladder cancer. Cancer. 1981;48:2154–2157.
   PubMed Web of Science ®Google Scholar
• Landolfo S, Guarini A, Riera L, et al. Chronic myeloid leukemia cells resistant to interferon-alpha lack STAT1 expression. Hematol J Off J Eur Haematol Assoc EHA. 2000;1:7–14.
   Google Scholar
• Sun WH, Pabon C, Alsayed Y, et al. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood. 1998;91:570–576.
   PubMed Web of Science ®Google Scholar
• Krysko DV, Garg AD, Kaczmarek A, et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer. 2012;12:860–875.
   PubMed Web of Science ®Google Scholar
• Schiavoni G, Sistigu A, Valentini M, et al. Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. Cancer Res. 2011;71:768–778.
   PubMed Web of Science ®Google Scholar
• Sistigu A, Yamazaki T, Vacchelli E, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med. 2014;20:1301–1309.
   PubMed Web of Science ®Google Scholar
• Cooper ZA, Frederick DT, Juneja VR, et al. BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes. Oncoimmunology. 2013;2:e26615.
   PubMed Web of Science ®Google Scholar